Linda Stein Gold, MD, is a dermatologist at Henry Ford Health. 

The panel explores patient attitudes toward oral vs injectable treatments and practical limitations of current oral agents.

Current Gaps in Psoriasis Care: Tolerability, Efficacy, and Rate of Response

, despite the expanding therapeutic landscape. Linda Stein Gold, MD, and her colleagues analyze patient- and provider-reported data from the 

 surveys, revealing that many patients remain dissatisfied with current therapies and that oral agents are overwhelmingly preferred over injectables. The experts discuss how patient lifestyle, comorbidities, and psychosocial burden influence shared decision-making and treatment adherence. They also interpret the 

International Psoriasis Council’s (IPC)

 and explore its implications for reducing “topical churn” and advancing systemic therapy earlier in the disease course.

 and its potential to close current gaps in care. The panel provides an in-depth review of the 

 clinical development program, summarizing the 

 trials, which demonstrated superior efficacy versus deucravacitinib at both 16 and 24 weeks, with favorable safety and tolerability. They also discuss new 

 showing sustained clearance and no new safety signals in adults and adolescents. The faculty reflect on ICO’s implications for adolescent psoriasis and how early, aggressive oral intervention may help prevent progression to psoriatic arthritis, marking a significant milestone in the evolution of oral IL-23–targeted therapy.

The final portion of the series shifts focus to 

managing active psoriatic arthritis (PsA)

. The experts discuss new findings from the 

 demonstrated the first clear evidence of IL-23–mediated inhibition of structural joint damage, reinforcing the rationale for early biologic use in high-risk patients. They compare APEX to prior IL-23 studies, discuss implications for therapy sequencing, and highlight other emerging data from 

 studies. In closing, Stein Gold and colleagues emphasize a forward-looking approach that integrates personalized therapy selection, early detection of PsA, and cross-specialty collaboration to elevate standards of psoriasis care

Videos

The panel explores patient attitudes toward oral vs injectable treatments and practical limitations of current oral agents.


Video Series

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Managing Pediatric AD With New Topicals

Panelists discuss how new nonsteroidal treatments are transforming the management of pediatric atopic dermatitis (AD) by combining efficacy, safety, and convenience. Simplified regimens encourage better adherence, while gentle formulations support long-term use without irritation or systemic risks.

They emphasize the role of caregiver education—teaching families how to maintain treatment routines and address flares early helps sustain progress. Consistent communication builds trust and improves outcomes, allowing children to live more comfortably and confidently.

Panelists conclude that integrating innovative therapies with supportive care strategies creates a balanced, sustainable approach to managing chronic AD in young patients.




Panelists discuss how new nonsteroidal therapies improve adherence, comfort, and long-term skin health for children with AD.

Peer Exchange

HCPLive® Peer Exchange panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's care professionals.

Understanding PCSK9 and Its Role in ASCVD Management

The panelists explore the biology and clinical relevance of PCSK9 in atherosclerotic cardiovascular disease (ASCVD) management. They explain that PCSK9 binds to LDL receptors, targeting them for degradation, which reduces hepatic clearance of LDL cholesterol and raises circulating levels. Beyond lipid metabolism, PCSK9 has pro-inflammatory effects, contributing to plaque formation and atherosclerosis progression, making it a compelling therapeutic target. The experts then distinguish between monoclonal antibody therapies, which neutralize PCSK9 in the circulation, and small interfering RNA (siRNA) therapies, which inhibit hepatic PCSK9 synthesis at the mRNA level. Both approaches achieve substantial LDL-C reduction, but siRNA-based treatments offer longer dosing intervals—typically twice yearly—potentially improving adherence and long-term outcomes. The panel underscores that PCSK9 inhibition represents a major advance in lipid management, complementing statins and other agents to achieve deeper, sustained LDL-C lowering and to address residual cardiovascular risk in high-risk ASCVD populations.

Explore the mechanisms and differences between PCSK9 inhibitors, including monoclonal antibodies and siRNA, in lowering LDL cholesterol effectively.

Ruxolitinib Efficacy and Safety in Pediatric AD

Panelists discuss how newer studies exploring JAK-targeting creams for children with mild to moderate atopic dermatitis (AD) demonstrate encouraging efficacy and sustained response. Many patients experience visible improvement and reduced itch within weeks, with benefits maintained over time.

Panelists also highlight favorable safety profiles, noting that adverse effects are generally mild and limited to the treatment area. These outcomes support expanding nonsteroidal options for children, reducing reliance on corticosteroids for long-term control.

Caregiver feedback reinforces the value of well-tolerated, easy-to-apply therapies that integrate smoothly into daily life, enhancing consistency and confidence.



Panelists discuss how JAK-targeting topical therapies offer effective, well-tolerated solutions for children with mild to moderate AD.

Review of the updated IPC framework defining topical failure, reducing “topical churn,” and guiding earlier systemic escalation.

An Overview of Treat-to-Target in Psoriasis 

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Articles

Novo Nordisk has terminated the 1-year follow-up for the evoke and evoke+ trials after no significant reduction was indicated in either.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Geriatrics

Geriatric medicine condition center page is a comprehensive resource for clinical news and insights on frequent geriatric-related diseases and conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for sleep disorder, dementia, Alzheimer's disease, and more.

Dementia and Alzheimer Disease

Alzheimer Disease condition center page, resources on the topics of medical news and expert insight into Alzheimer's can be found. Content includes articles, interviews, videos, podcasts, and breaking news on dementa and Alzheimer disease research, treatment, and drug development.

Semaglutide Fails to Demonstrate Reduction in Alzheimer’s Progression Versus Placebo

Sayna Norouzi, MD, is an assistant professor of medicine, clinical nephrologist, and founder and director of the glomerular disease and polycystic kidney disease clinics at Loma Linda University Medical Center.

The panel discusses how clinicians assess progression in IgA nephropathy and the importance of recognizing high-risk patients early. They emphasize that proteinuria is a central prognostic marker, and that achieving sustained reduction is critical. However, they note that ongoing eGFR decline, even when proteinuria appears improved, signals continued immune-mediated injury and should prompt re-evaluation. The group then addresses diagnostic challenges, including the fact that many patients first present after significant kidney damage has already occurred. To improve early detection, they support lowering the biopsy threshold to persistent proteinuria around 0.5 g/day, particularly when accompanied by hematuria. Increased awareness among primary care clinicians is highlighted as essential for earlier referral. Finally, the discussion includes the role of the RaDaR Registry, which collects long-term real-world data to help identify progression patterns and refine risk stratification. Overall, the segment underscores the need for early diagnosis and vigilant monitoring.

RaDaR Insights on Proteinuria, eGFR Decline, and Diagnostic Challenges in IgAN

In this segment, the panelists discuss IgA Nephropathy, a glomerular disease primarily affecting young adults in their 20s and 30s. The condition has a slight predilection for males and Southeast Asians. Patients typically present asymptomatically with blood or protein in urine, or with gross hematuria following a respiratory tract infection. Less commonly, patients may develop severe nephrotic syndrome.
Clinicians are most concerned with proteinuria and kidney function. Patients with proteinuria exceeding 0.5 grams are considered at risk for disease progression. The panel emphasizes that diagnoses often occur too late, with patients already having lost nearly half their kidney function. This is particularly critical because these young patients have decades ahead of them, and even small annual kidney function losses can lead to end-stage kidney disease, potentially requiring dialysis. The early detection and monitoring of these patients are crucial for preserving long-term kidney health.


Clinical and Laboratory Findings Suggestive of IgA Nephropathy (IgAN)

Joseph Gatti, DMSc, MPAS, MBA, PA-C, is the founder of the Clinic for Dermatology & Wellness, LLC, and Pure Medspa, LLC. 

This interview at SDPA highlights Gatti's views on the impact of technology on radiology, pathology, and dermatology.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

AI’s Use in Non-Patient-Facing Dermatology Spaces, With Joseph Gatti, DMSc, MPAS, MBA, PA-C

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

Bariatric surgery, particularly sleeve gastrectomy, may improve survival and kidney transplant access in older adults with obesity and ESKD.


Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Chronic Kidney Disease

Bariatric Surgery Type Impacts Survival for Older Patients with ESKD

Jason Hawkes, MD, MS, outlines key factors influencing the selection between biologics, oral small molecules, and traditional systemic therapies in CSU management.

Considerations for Treatment Selection in CSU, With Jason Hawkes, MD, MS

The Underlying Causes of GCA: Environmental and Genetic Factors

Bayer’s investigational FXIa inhibitor has proven its superiority to placebo in reducing ischemic stroke risk without increasing major bleeding rate.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Stroke

On the HCPLive stroke page, resources on the topics of medical news and expert insight into CVA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on stroke medicine, and more.

OCEANIC-STROKE: Asundexian Achieves Primary Efficacy Endpoint in Patients with Ischemic Stroke

Jason Hawkes, MD, MS, discusses recent advances in the management of chronic spontaneous urticaria, focusing on the transition to new targeted therapies.

Latest News

Current Gaps in Psoriasis Care: Tolerability, Efficacy, and Rate of Response

Managing Pediatric AD With New Topicals

Understanding PCSK9 and Its Role in ASCVD Management

Ruxolitinib Efficacy and Safety in Pediatric AD

An Overview of Treat-to-Target in Psoriasis